STAT News probed questionable business practices at Proove Biosciences, a company making genetic tests purported to assess the risk of opioid addiction. The story quotes a former employee as saying the CEO is "in it for the money. He wanted to swab as many people as possible." A MedPage Today report last year raised questions about a dearth of data behind the company's tests.
Can Axovant succeed where so many have others have failed in Alzheimer's? Results from its phase III trial of intepirdine (RVT-101) will report out in the third quarter of this year. (STAT Plus)
Genentech thinks it, too, may have what it takes to succeed in Alzheimer's. It's launching a phase III trial of crenezumab in 750 patients with prodromal or mild Alzheimer's disease. The anti-amyloid antibody has already failed a mid-stage program, but the company is optimistic about positive effects on cognitive and functional scores for those in the earliest stages of disease. (Endpoints News)
Meanwhile, another theory of Alzheimer's suffered a blow. A drug aimed at boosting intracerebral glucose metabolism, thought by some to trigger amyloid buildup in the brain, failed to make a clinical difference in patients with mild-moderate disease. (Reuters)
A CRISPR/Cas9 solution for Duchenne muscular dystrophy? Startup Exonics Therapeutics is looking to move on from mouse trials, which saw an 80% boost in dystrophin production. (Endpoints News)
A Copaxone generic is facing delays after the FDA slapped Pfizer with a warning letter about manufacturing infractions at one of its facilities. (BioPharma Dive)
This article was published first by MedPageToday NeuroBreak: More Trouble for Opioid Genetic Risk Test, a trusted and reliable source for clinical and policy coverage, and free Continuing Medical Education (CME), that directly affects the lives and practices of health care professionals.